| Literature DB >> 35056823 |
Renzhu Pang1, Qunyan Zhu2, Jia Wei1,2, Xianying Meng1, Zhenxin Wang2,3.
Abstract
Paper-based analytical devices (PADs), including lateral flow assays (LFAs), dipstick assays and microfluidic PADs (μPADs), have a great impact on the healthcare realm and environmental monitoring. This is especially evident in developing countries because PADs-based point-of-care testing (POCT) enables to rapidly determine various (bio)chemical analytes in a miniaturized, cost-effective and user-friendly manner. Low sensitivity and poor specificity are the main bottlenecks associated with PADs, which limit the entry of PADs into the real-life applications. The application of nanomaterials in PADs is showing great improvement in their detection performance in terms of sensitivity, selectivity and accuracy since the nanomaterials have unique physicochemical properties. In this review, the research progress on the nanomaterial-based PADs is summarized by highlighting representative recent publications. We mainly focus on the detection principles, the sensing mechanisms of how they work and applications in disease diagnosis, environmental monitoring and food safety management. In addition, the limitations and challenges associated with the development of nanomaterial-based PADs are discussed, and further directions in this research field are proposed.Entities:
Keywords: nanomaterials; paper-based analytical devices; point-of-care testing; signal enhancement
Mesh:
Year: 2022 PMID: 35056823 PMCID: PMC8779822 DOI: 10.3390/molecules27020508
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The annual publications numbers from 1 January 2015 to 30 October 2021 on the keywords: (a) (1) paper-based analytical devices and paper-based analytical devices plus (2) electrochemical, (3) colorimetric, (4) fluorescence, (5) Raman; and (b) (1) paper-based analytical devices plus nanoparticle/nanoparticles, and paper-based analytical devices plus nanoparticle or nanomaterial plus (2) electrochemical, (3) colorimetric, (4) fluorescence, (5) Raman. The data were obtained from Web of ScienceTM.
Figure 2Outline of nanomaterial-based paper-based analytical devices.
Figure 3An illustration of a typical electrochemical paper-based analytical device.
The typical nanomaterial-enhanced ePADs for sensing various analytes.
| Nanomaterials | Modification Methods | Electrochemical Method | Analytes | Linear Ranges | Limit of Detection | Real Samples | Recovery | Ref. |
|---|---|---|---|---|---|---|---|---|
| AuNPs | In situ growth | DPV | CEA and PSA | 5 × 10−3 to 100 ng mL−1 (CEA) and 2 × 10−3 to 40 ng mL−1 (PSA) | 2 × 10−3 ng mL−1 (CEA) 1 × 10−3 ng mL−1 (PSA) | Human serum | - | [ |
| AuNPs | Electrodeposition | DPV | CRP | 5 to 5 × 103 ng mL−1 | 1.6 ng mL−1 | Certified human serum | - | [ |
| AuNPs | Electrodeposition | DPV | EGFR | 0.5 to 500 nmol L−1 | 0.167 nmol L−1 | Saliva samples | - | [ |
| AuNPs | Drop-casting | DPV | H1047R (A3140G) missense mutation in exon 20 | - | 5 nmol L−1 (signal on) and 6 nmol L−1 (signal off) | - | - | [ |
| AuNPs | Electrodeposition | Impedimetry | miRNA 155 | 0 to 4 × 103 ng mL−1 | 6.9 × 102 ng mL−1 (93.4 nmol L−1) | Fetal bovine serum | - | [ |
| AuNPs | Drop-casting | SWASV | Hg2+ | 5 to 200 ng mL−1 | 2.5 ng mL−1 | Drinking water | 95% to 104% | [ |
| Poly (N-vinylpyrolidone) AuNPs | Screen-printing | Chronoamperometry | Glucose | 1 × 104 to 1.5 × 106 nmol L−1 | 2.6 × 104 nmol L−1 | - | - | [ |
| Poly (N-vinylpyrolidone) AuNPs | Screen-printing | DPV | CEA | 1 to 100 ng mL−1 | 0.33 ng mL−1 | Diluted human serum | 99.58% to 102.50% | [ |
| Pd decoration of Cu/Co-doped CeO2 (CuCo-CeO2-Pd) nanospheres and urchin-like AuNPs | In situ growth | DPV | Amyloid-β | 1 × 10−3 to 100 nmol L−1 | 5 × 10−5 nmol L−1 | Artificial cerebrospinal fluid and human serum | 99% to 100.5% | [ |
| N-CDs, TiO2 NPs and Pt NPs | Drop-casting | PEC | CEA | 2 × 10−3 to 200 ng mL−1 | 1.0 × 10−3 ng mL−1 | Living MCF-7 cells | - | [ |
| TiO2 nanosheets and CeO2 NPs | In situ growth of TiO2 nanosheets and drop-casting of CeO2 NPs | PEC | Thrombin | 2 × 10−5 to 0.1 nmol L−1 | 6.7 × 10−6 nmol L−1 | Human serum | - | [ |
| CdSe/CdS magic-sized QDs | Drop-casting | DPV | Dopamine | 500 to 1.5 × 104 nmol L−1 | 96 nmol L−1 | Human serum | 95.2% to 102.6% | [ |
| ZnO NPs | Drop-casting | SWV | Picric acid | 4 × 103 to 6 × 104 nmol L−1 | 4.04 × 103 nmol L−1 | Tap water, lake water | 92.3% to 98.9% | [ |
| Molecularly imprinted polymer coated Fe3O4@Au@SiO2 NPs | Drop-casting | LSV | Serotonin | 10 to 106 nmol L−1 | 2 nmol L−1 | Pharmaceutical capsules and urine samples | 100% to 111% | [ |
| Patchy gold coated Fe3O4 nanospheres | - | ECL | CEA | 1 × 10−4 ng mL−1 to 15 ng mL−1 | 3 × 10−5 ng mL−1 | Human serum | - | [ |
| Cubic Cu2O-Au NPs and AgNPs | In situ growth (AgNPs) | ECL | Ni2+ and Hg2+ | 10 to 2 × 105 nmol L−1 (Ni2+) and 1 × 10−2 nmol L−1 to 1 × 103 nmol L−1 (Hg2+) | 3.1 nmol L−1 (Ni2+) and 3.8 × 10−3 nmol L−1 (Hg2+) | Lake water | 96.4% to 101.6% (Ni2+) and 96.0% to 104.0% (Hg2+) | [ |
| DNA-functionalized PtCu nanoframes | - | ECL | Streptavidin | 1 × 10−4 nmol L−1 to 100 nmol L−1 | 3.34 × 10−5 nmol L−1 | Human serum | 98.4% to 106.5% | [ |
| SWCNTs | Vaccum filtration | CV | Glucose | 5 × 10−5 to 1 × 107 nmol L−1 | 1.48 × 105 nmol L−1 | Coke | 97.3% to 105% | [ |
| Graphene | Screen-printing | DPV | Oxytetracycline | 1 to 200 ng mL−1 | 0.33 ng mL−1 | Milk, honey and shrimp | - | [ |
| Graphene | Screen-printing | DPV | Hepatitis B virus DNA | 5 × 10−2 to 100 nmol L−1 | 1.45 × 10−3 nmol L−1 | Plasmid constructs | - | [ |
| Graphene | Screen-printing | SWV | Salivary thiocyanate | 2.5 × 104 to 7 × 105 nmol L−1 | 6 × 103 nmol L−1 | Human saliva | - | [ |
| Graphene | Drop-casting | DPV | ATP | 3 × 102 to 4.5 × 105 nmol L−1 | 80 nmol L−1 | Human serum and cell lysates | 95.4% to 104.2% | [ |
| Graphene and CuNPs | Screen-printing (graphene) and in situ growth CuNPs | DPV | NOx | 0 to 150 vppm | 0.23 vppm | Ambient indoor and outdoor air, and exhaust gases | - | [ |
| Graphene and AuNPs | Drop-casting (graphene) and label (AuNPs) | DPV | Pseudopodium-enriched atypical kinase one | 1 × 10−2 to 1 × 103 ng mL−1 | 1 × 10−2 ng mL−1 | Human serum | 103% to 104% | [ |
| (NH2-G)/Thi/AuNPs nanocomposites | Drop-casting | DPV | CEA | 5 × 10−2 to 500 ng mL−1 | 1 × 10−2 ng mL−1 | Human serum | - | [ |
| (NH2-G)/Thi/AuNPs nanocomposites | Drop-casting | DPV | CEA and NSE | 1 × 10−2 to 500 ng mL−1 for CEA and 5 × 10−2 to 500 ng mL−1 for NSE | 2 × 10−3 ng mL−1 for CEA and 1 × 10−2 ng mL−1 for NSE | Human serum | - | [ |
| Reduced graphene | Screen-printing and in situ EC reduction | Amperometry | Claudin 7 and CD81 | 2 × 10−3 to 1 ng mL−1 (Claudin 7) and 0.01 to 10 ng mL−1 (CD81) | 4 × 10−4 ng mL−1 (Claudin 7) and 3 × 10−3 ng mL−1 (CD81) | Plasma of breast cancer patients | - | [ |
| Reduced graphene | Drop-casting and EC reduction | SWV | Ethinylestradiol | 5 × 10−4 to 0.12 ng mL−1 | 1 × 10−4 ng mL−1 | River water | 97.5% to 103.7% | [ |
| Graphene QDs | Drop-casting | SWV | UA and creatinine | 10 to 3 × 103 nmol L−1 | 8.4 nmol L−1 (UA) and 3.7 nmol L−1 (Creatinine) | Human urine | 98.9% to 101.5% | [ |
| GO | Drop-casting | SWV | CRP, cTnI and PCT | 1 to 1 × 105 ng mL−1 (CRP), 1 × 10−3 to 250 ng mL−1 (cTnI), 5 × 10−4 ng mL−1 to 250 ng mL−1 (PCT) | 0.38 ng mL−1 (CRP), 1.6 × 10−4 ng mL−1 (cTnI) and 2.7 × 10−4 ng mL−1 (PCT) | Human serum | - | [ |
| RGO and cysteine AuNPs | Drop-casting (RGO) and electrodeposition (AuNPs) | Chronoamperomatriy | IL-8 | 1 × 10−3 to 9 × 10−3 ng mL−1 | 5.89 × 10−4 ng mL−1 | - | - | [ |
| (NH2-GO)/Thi/AuNPs | Screen-printing | DPV | EGFR | 5 × 10−2 to 200 ng mL−1 | 5 × 10−2 ng mL−1 | Human serum | - | [ |
| rGO/Thi/S-AuNP/Chi | Drop-casting | Amperometry | 17β-E2 | 1 × 10−2 to 100 ng mL−1 | 1 × 10−2 ng mL−1 | Human serum | - | [ |
| Cobalt-MOF | In situ growth | Amperometry | Glucose | 8 × 105 to 1.6 × 107 nmol L−1 | 1.5 × 105 nmol L−1 | Serum, Urine and Saliva | 87.2% to 108.6% | [ |
| Pd@hollow Zn/Co core−shell ZIF67/ZIF8 NPs | Drop-casting | DPV | PSA | 5 × 10−3 ng mL−1 to 50 ng mL−1 | 7.8 × 10−4 ng mL−1 | - | - | [ |
| Ni-MOFs/AuNPs/MWCNTs/PVA | Vacuum filtration (MWCNT/PVA) and drop-casting (Ni-MOFs/AuNPs) | DPV | HIV DNA | 10 to 1 × 103 nmol L−1 | 0.13 nmol L−1 | Human serum | 95.5% to 103.8% | [ |
CV: cyclic voltammetry; SWV: square wave voltammetry; ECL: electrochemical luminescence; PEC: photoelectrochemical; DPV: differential pulse voltammetry; EIS: electrochemical impedance spectroscopy; ASV: anodic stripping voltammetry; LSV: linear-sweep voltammetry; SWASV: square wave anodic stripping voltammetry; 2D: two dimension; 3D: three dimension; NPs: nanoparticles; AuNPs: gold nanoparticles: CDs: carbon dots; N-CDs: nitrogen-doped carbon dots; QDs: quantum dots; AgNPs: silver nanoparticles; SWCNTs: single-walled carbon nanotubes; MWCNTs: multiple-walled carbon nanotubes; MOFs: metal-organic frameworks; Ni-MOFs: nickel metal-organic frameworks; CuNPs: copper nanoparticles; (NH2-G)/Thi/AuNPs: amino functionalized graphene/thionine/gold nanoparticles nanocomposites; RGO: reduced graphene oxide; GO: graphene oxide; rGO/Thi/S-AuNP/Chi: amino redox graphene/thionine/streptavidin-modified gold nanoparticles/chitosan; ZIF: zeolite imidazole ester framework material; PVA: polyvinyl alcohol; CEA: carcinoembryonic antigen; PSA: prostate-specific antigen; CRP: C-reactive protein; EGFR: epidermal growth factor receptor; NSE: neuronspecific enolase; ATP: adenosine triphosphate; UA: uric acid; IL-8: interleukin 8; cTnI: cardiac troponin I; PCT: procalcitonin.
Figure 4An illustration of a typical colorimetric paper-based analytical device.
The typical nanomaterial-enhanced colorimetric PADs for sensing various analytes.
| Nanomaterials | Analytes | Linear Ranges | Limit of Detection | Real Samples | Recovery | Ref. |
|---|---|---|---|---|---|---|
| AuNPs | Gallic acid | 1 × 104 to 1 × 106 nmol L−1 | 1 × 103 nmol L−1 | Tea | 85.2% to 93.1% | [ |
| Avidin functionalized AuNPs | Ig G | - | 300 ng mL−1 | - | - | [ |
| Citrate stabilized AuNPs | Melamine | 100 to 106 ng mL−1 | 100 ng mL−1 | Milk | - | [ |
| Citrate stabilized AuNPs | NADH | - | 1.25 × 104 nmol L−1 | Cell Lysate | - | [ |
| Aspartic acid modified AuNPs | Cysteine | 9.99 × 104 to 9.987 × 105 nmol L−1 | 1 × 103 nmol L−1 | Human plasma | 99.2% to 101.1% | [ |
| ssDNA-PEI-Au-PS | Hg2+ and As3+ | 0 to 3 × 104 ng mL−1 | 1 × 103 ng mL−1 | River water | 96.2% to 116.7% | [ |
| ssDNA functionalized AuNPs | Tuberculosis DNA | 1.95 × 10−2 to 19.5 ng mL−1 | 1.95 × 10−2 ng mL−1 | Infected tissue | - | [ |
| ssDNA functionalized AuNPs | PSA | - | 1 × 10−2 ng mL−1 | Human serum | - | [ |
| Antibody functionalized AuNPs | Ig G | - | 284.52 ng mL−1 | Whole blood | - | [ |
| Antibody functionalized AuNPs | Yersinia Pestis | - | 2.5 × 10−2 ng mL−1 | - | - | [ |
| Antibody functionalized AuNPs | Influenza A H1N1 and H3N2 viruses | - | 2.7 × 103 pfu/assay for H1N1 detection and 2.7 ×104 pfu/assay for | Cell lysate | - | [ |
| Antibodies functionalized AuNRs | sIL-2R | 1 to 6.25 × 103 ng mL−1 | 1.0 ng mL−1 | Mouse serum | 93% to 109% | [ |
| Antibodies functionalized AuNRs | CRP | 50 to 1 × 104 ng mL−1 | 1.3 ng mL−1 | Human plasma | - | [ |
| Co(II) catalyst, secondary antibody, luminol multifunctionalized AuNPs | H-FABP, cTnI and copeptin | 1 × 10−4 to 1 × 103 ng mL−1, 5 × 10−4 to 1 × 103 ng mL−1 and 1 × 10−3 to 1 × 106 ng mL−1 for H-FABP, cTnI and copeptin | 6 × 10−5 ng mL−1, 3 × 10−4 ng mL−1 and 4 × 10−4 ng mL−1 for H-FABP, cTnI and copeptin | Human serum | 94% to 108% | [ |
| Cu/Co-doped CeO2 (CuCo-CeO2-Pd) nanospheres and urchin-like AuNPs | Amyloid-β | 1 × 10−2 to 100 nmol L−1 | 5 × 10−4 nmol L−1 | Artificial cerebrospinal fluid (aCSF) and human serum | 99% to 100.5% | [ |
| Gold nanostars | Glucose | 0 to 2 × 107 nmol L−1 | 1.4 × 106 nmol L−1 | - | - | [ |
| PVP stabilized AgNPs | Nitrite | 10 to 5 × 103 nmol L−1 and 104 to 3.2 × 106 nmol L−1 | 8.5 × 10−2 nmol L−1 | Tap, river and lake water | 95.6% to 101.9% | [ |
| PVP stabilized AgNPs | Hg2+ | 40 to 1.2 × 103 ng mL−1 | 10 ng mL−1 | Tube well, river pond water, industrial waste and coal mine water | 92.5% to 96.0% | [ |
| PVP stabilized AgNPs | Ascorbic acid | 1 × 106 to 4 × 106 nmol L−1 | 8.28 × 104 nmol L−1 | Vitamin C tablet and artificial juice | - | [ |
| Citrate stabilized AgNPs | Cr3+ and Cl− | 50 to 1 × 103 ng mL−1 (Cr3+) and 1 × 104 to 5 × 105 ng mL−1 (Cl−) | 15 ng mL−1 (Cr3+) and 1 × 104 ng mL−1 (Cl−) | Instant noodle seasoning | - | [ |
| Citrate stabilized AgNPs | Hg2+ | 1 to 4 ng mL−1 | 0.86 ng mL−1 | River water | 98.9% to 101% | [ |
| Achillea Wilhelmsii extract coated AgNPs | Hg2+ | 1 × 103 to 7 × 105 nmol L−1 | 300 nmol L−1 | River, well and lake water | - | [ |
| Citrate capped Cu@Ag core@shell NPs | Phenthoate | 50 to 1.5 × 103 ng mL−1 | 15 ng mL−1 | Pond and river water, cucumber and potato | 92.6% to 97.4% | [ |
| DNA-templated Ag/Pt NCs | miRNA21 | 1 × 10−3 to 0.7 nmol L−1 | 6 × 10−4 nmol L−1 | Human urine | 93.8% to 106.0% | [ |
| ssDNA functionalized PtNPs | miRNAs | 1 × 10−2 to 100 nmol L−1 | 8.5 × 10−3 nmol L−1 (miRNA21) | Human Serum | 86.2% to 112.2% | [ |
| Pd NPs/meso-C | H2O2 | 5 × 103 to 3 × 105 nmol L−1 | 1 × 103 nmol L−1 | Commercial milk | 100.9% to 109.7% | [ |
| ZnONRs | Glucose and UA | Glucose (1 × 104 to 1 × 107 nmol L−1) and uric acid (1 × 104 to 5 × 106 nmol L−1) | 3 × 103 nmol L−1 for glucose and 4 × 103 nmol L−1 for uric acid | Human serum and urine | 89% to 109% | [ |
| Cr2O3-TiO2 nanocomposites | H2O2 | 5 to 1 × 105 nmol L−1 | 3 nmol L−1 | Tap water, milk and fetal bovine serum (FBS) albumin | 95.8% to 98% | [ |
| Mn-ZnS QDs | Glyphosate | 5 to 5 × 104 ng mL−1 | 2 ng mL−1 | Whole grain | 80.6% to 119.9% | [ |
| N-CDs | H2O2 | 5 × 104 to 1 × 107 nmol L−1 | 1.4 × 104 nmol L−1 | Human plasma | 91.0% to 113.0% | [ |
| CDs@Eu/GMP ICPs | Cerebral acetylcholinesterase | 0.1 mU mL−1 to 60 mU mL−1 | 0.033 mU mL−1 | Brain tissues and cerebral fluid | - | [ |
| Carbon nitride nanoparticles | Tetracycline | 800 to 4 × 105 nmol L−1 | 120 nmol L−1 | Shrimp samples and river water | 98.7% to 102.8% | [ |
| Poly(L-lactic acid) nanofibers | Glucose | 1 × 105 to 5 × 106 ng mL−1 | 1 × 105 ng mL−1 | - | - | [ |
| Cobalt (II)-terephthalate MOFs | Glucose | 5 × 104 to 1.5 × 107 nmol L−1 | 3.2 × 103 nmol L−1 | Human blood | 96.9% to 102.6% | [ |
ssDNA-PEI-Au-PS: single strand DNA (ssDNA) functionalized polyethyleneimine (PEI) encapsulation of gold-decorated polystyrene (PS) core particles; AgNPs: silver nanoparticles; PVP: poly(vinylpyrrolidone); NCs: nanoclusters; PdNPs: palladium nanoparticles; Pd NPs/meso-C: mesoporous carbon-dispersed PdNPs; PtNPs: platinum nanoparticles; AuNRs: gold nanorods; ZnONRs: zinc oxide nanorods; Ig G: immunoglobulin G; NADH: aihydronicotinamide adenine dinucleotide; H-FABP: heart-type fatty acid-binding protein; sIL-2R: soluble interleukin-2 receptor.
The typical nanomaterial-enhanced fluorescent PADs for sensing various analytes.
| Nanomaterials | Analytes | Linear Ranges | Limit of Detection | Real Samples | Recovery | Ref. |
|---|---|---|---|---|---|---|
| AuNCs/MIL-68(In)-NH2/Cys | Hg2+ | 0.02 nmol L−1 to 200 nmol L−1 and 200 to 6 × 104 nmol L−1 | 6.7 × 10−3 nmol L−1 | Tap and Lake water | 91.3% to 110.2% | [ |
| γG-AuNCs | L-kynurenine (Kyn) | - | 5 × 103 nmol L−1 | Artificial cerebrospinal fluid | - | [ |
| BSA-AuNCs | Iodate | 5 × 103 to 1 × 105 nmol L−1 | 5 × 103 nmol L−1 | Iodized salts and fish sauces | 90.5% to 102% | [ |
| PVP-supported CuNCs | Iodine | 100 to 500 ng mL−1 | 29 ng mL−1 | - | 97% to 108% | [ |
| Graphitic carbon nitride nanosheets and ssDNA functionalized PdNCs | Let-7a | 5 × 10−2 to 1 × 103 nmol L−1 (Colorimetry) and 1 × 10−5 to 1 nmol L−1 (Fluorescence) | 1.6 × 10−2 nmol L−1 (Colorimetry) and 3 × 10−6 nmol L−1 (Fluorescence) | Human serum | 91% to 110% | [ |
| Imprinted polymer grafted CdTe QDs | Cu2+, Cd2+, Pb2+ and Hg2+ | - | 10 ng mL−1 (Cu2+), 7 ng mL−1 (Cd2+), 9 ng mL−1 (Pb2+) and 15 ng mL−1 (Hg2+) | Seawater | - | [ |
| CdTe QDs | Ag+ and Ag NPs | 50 to 1.1 × 104 ng mL−1 (Ag+) | 50 ng mL−1 (Ag+) | River water and antibacterial Products | 94% to 115% | [ |
| CdTe QDs | 2,4-dichlorophenoxyacetic acid | 560 to 8 × 104 nmol L−1 | 90 nmol L−1 | soybean sprouts and lake water | 86.2% to 109.5% | [ |
| Mercaptosuccinic-acid capped CdTe QDs | Arsenic | 50 to 3 × 104 ng mL−1 | 16 ng mL−1 | Water | 92% to 112% | [ |
| Silica-embedded CdTe QDs functionalized with rhodamine derivative | Fe3+ | 0 to 3.25 × 103 nmol L−1 | 26.5 nmol L−1 | Lake water and river water | 94.2% to 106.0% | [ |
| Polythiophene-coated CdTe QDs | Acetylcholinesterase | - | 2.13 U L−1 | Human serum | 107% to 112% | [ |
| Antibody functionalized CdTe QD and Au NPs | Immunoglobulin G | 10 to 100 ng mL−1 | 0.4 ng mL−1 | Human serum | 97% to 104% | [ |
| CdTe QDs and antibody functionalized AgNPs | Matrix metalloproteinase-7 (MMP7) | 0.01 to 30 ng mL−1 | 7.3 × 10−3 ng mL−1 | Human serum | 91.7% to 113.3% | [ |
| CdTe QDs embedded SiNPs | Alpha fetoprotein (AFP) | 0.001 to 20 ng mL−1 | 400 ng mL−1 | Human serum | - | [ |
| CdTe/CdSe QDs | Carcinoembryonic antigen (CEA) | 0.05 to 20 ng mL−1 | 6.7 × 10−3 ng mL−1 | Human serum | - | [ |
| ZnSe QDs | Cd2+ and Pb2+ | 1 to 70 ng mL−1 (Cd2+) and 1 to 60 ng mL−1 (Pb2+) | 0.245 ng mL−1 (Ca2+) and 0.335 ng mL−1 (Pb2+) | Lake water and Seawater | 95.0% to 105.1% | [ |
| CdSexS1-x@ZnS (core@shell) QDs | Oligonucleotide biomarkers | - | 1.5 × 10−3 nmol | - | - | [ |
| GNR-QD core−shell embedded MOF structures | Benzaldehyde | 2 to 5 × 103 ng mL−1 | 1.2 ng mL−1 | Human exhalation | - | [ |
| ssDNA functionalized QDs coated MSNs and GO | MCF-7, HL-60 and K562 cells | 180 to 8 × 107 (MCF-7 cell), 210 to 7 × 107 (HL-60 cell) and 200 to 7 × 107 cells mL−1 (K562 cell) | 62 (MCF-7 cell), 70 (HL-60 cell) and 65 (K562 cell) cells mL−1 | - | - | [ |
| N-CDs | Hg2+ | 1 × 104 to 8 × 105 nmol L−1 | 10.7 nmol L−1 | - | - | [ |
| N-CDs | Hg2+ | 500 to 2.5 × 104 ng mL−1 | 500 ng mL−1 | Drinking, pond and tap water | 80% to 111% | [ |
| CDs | Folic acid | 1 × 103 to 3 × 105 nmol L−1 | 280 nmol L−1 | Orange juice and urine | 95.8% to 106.2% | [ |
| Blue CDs and red CDs | Pb2+ | 0 to 200 nmol L−1 | 2.89 nmol L−1 | Tap water and lake water | 92.8% to115.2% | [ |
| CDs and hexametaphosphate capped AuNPs | Ca2+, Mg2+ and F− | 0 to 4.5 × 105 nmol L−1 (F−) | 2.1 × 104 nmol L−1 (F−) | Ground water | 96.2% to 109.5% | [ |
| ssDNA functionalized N-CDs and ssDNA functionalized CeO2 NPs | miRNAs | 1 × 10−7 to 1 nmol L−1 (miRNA210) and 2 × 10−7 to 2 nmol L−1 (miRNA21) | 3 × 10−8 nmol L−1 (miRNA210) and 6 × 10−8 nmol L−1 (miRNA21) | Cell lysates | 96.9% to 103.0% | [ |
| CDs@Eu/GMP ICPs | Acetylcholinesterase | 0 to 60 mU mL−1 | 2 mU mL−1 | Brain tissues and cerebrospinal fluid (CSF) | 98.3% to 98.8% | [ |
| UCNPs | Immunoglobulin E (IgE) | 0.5 to 50 IU mL−1 | 0.13 IU mL−1 | Human serum | - | [ |
| Eu@SiNPs | - | 2.38 × 104 spore mL−1 | Yellow river water, tap water and soil | 92.9% to 106.9% | [ | |
| NH2-MIL-125(Ti) MOF and GDH/antibody functionalized AuNPs | CEA | 0.1 to 200 ng mL−1 | 0.041 ng mL−1 | Human serum | - | [ |
| Eu-DPA/PTA-NH2 MOF | H2O | 0 to 100% | 0.01% | Weisu granule, Cefuroxime axetil capsule and Azithromycin capsule | - | [ |
| Cu(II)-Pyrazolate-based porphyrinic MOFs | Dopamine | 2.5 to 1 × 103 nmol L−1 | 2.5 nmol L−1 | Human serum | - | [ |
| Al-MOF nanosheet | Malachite green | 500 to 2 × 105 ng mL−1 | 1.6 × 103 ng mL−1 | Fish tissue | 91.0% to 108.8% | [ |
AuNCs: gold nanoclusters; AuNCs/MIL-68(In)-NH2/Cys: glutathione stabilized AuNCs/indium-based MOFs modified with cysteine; BSA-AuNCs: bovine serum albumin-stabilized AuNCs; γG-AuNCs: γ-globulin (γG) immunoprotein stabilized AuNCs; SiNPs: silica nanoparticles; MSNs: mesoporous silica nanoparticles; UCNPs: upconversion nanoparticles; Eu@SiNPs: europium (Eu)-doped silicon nanoparticles; GDH: glutamate dehydrogenase; Eu-DPA/PTA-NH2 MOF: Eu-dipicolinic acid/2-aminophthalic acid MOF; ICP: ion concentration polarization.
Figure 5Schematic diagram of a typical fluorometric paper-based analytical device.
Figure 6Schematic diagram of a typical paper-based surface-enhanced Raman spectroscopic analytical device.
The typical nanomaterial-based SERS PADs for sensing various analytes.
| Nanomaterials | Analytes | Linear Ranges | Limit of Detection | Real Samples | Recovery | Ref |
|---|---|---|---|---|---|---|
| GNR-QD core−shell embedded MOF structures | Benzaldehyde | 0.1 to 10 ng mL−1 | 0.1 ng mL−1 | Human exhalation | - | [ |
| GNRs | Fluorescein and napthalenethiol | - | ∼1 × 10−7 nmol L−1 (Fluorescein) and 5 × 10−10 nmol L−1 (Naphtalenethiol) | Tap water | - | [ |
| GNRs modified with 4-mercaptophenylboronic acid (4-MBA) and 1-decanethiol (1-DT) molecules | Glucose | 5 × 105 to 1 × 107 nmol L−1 | 1 × 105 nmol L−1 | Blood | 88% | [ |
| AuNPs | Cocaine | - | 10 ng mL−1 | Human plasma | - | [ |
| AuNPs | Age-related macular degeneration aqueous humors: THV-I1043, THV-I1454 and THV-I1656 | - | - | Aqueous humors | - | [ |
| AuNPs | Clenbuterol | 1 × 10−4 to 1 × 102 ng mL−1 | 1 × 10−4 ng mL−1 | Swine hair | 104.8% to 116.2% | [ |
| AgNPs | P-selectin | 100 to 500 ng mL−1 | 104.2 ng mL−1 (ca. 0.7 nmol L−1) | - | - | [ |
| Flower-like AgNPs | Chloramphenicol | 1 × 10−2 to 1 × 105 ng mL−1 | 1 × 10−2 ng mL−1 | Pork | 90% to 102% | [ |
| Silver nanocubes | Adenine | 10 to 1 × 105 nmol L−1 | 0.89 nmol L−1 | Urine | 89% to 107% | [ |
| 4-aminothiophenol-modified rGO/ Ag NPs | Formaldehyde (FA) and acetaldehyde (AA) | 4.5 × 10−4 to 480 ng mL−1 | 1.5 × 10−4 ng mL−1 (FA) and 1.3 × 10−3 ng mL−1 (AA) | Wine and human urine | 104.6% to 112.8% | [ |
| ssDNA functionalized anisotropic AgNPs | Has-miR-21 | - | 1 pmol L−1 | - | - | [ |
| Strawberry-like SiO2/Ag nanocomposites | Acrylamide | 0.1 to 5 × 104 nmol L−1 | 0.02 nmol L−1 | Cookies, chips and bread | 80.5% to 105.6% | [ |
| Silver coated AuNPs functionalized with 4-Mercapto Pyridine and glucose or 4-mercapto pyridine and biotin. | Streptavidin and concanavalin A | - | 1 × 10−5 nmol L−1 (Streptavidin) and 1 × 10−6 nmol L−1 (Concanavalin A) | - | - | [ |
| 4-mercaptopyridine (Mpy)-modified GNRs-rGO hybrids | SO2 | 1 × 103 to 2 × 106 nmol L−1 | 1 × 103 nmol L−1 | Wine | 87.1% to 116.8% | [ |
| ZnO NPs | SO2 | 5 × 103 to 3 × 105 ng mL−1 | 2 × 103 ng mL−1 | Wine | - | [ |
| MoO3−X nanosheets | Rhodamine 6G | - | 100 nmol L−1 | - | - | [ |
The comparison of four representative detection methods of PADs.
| Detection Methods | The Main Nanomaterials | Advantages | Disadvantages | Limit of Detection | Ref. |
|---|---|---|---|---|---|
| EC PADs | AuNPs, graphene, MOF, multiple metallic NPs composites and functionalized NPs | High sensitivity, rapid response and easy miniaturization | Equipment-dependent, complicated operation, easy interfered with complex matrices | 1 pg mL−1 level for AuNPs, 0.1 pg mL−1 level for graphene, 0.1 mmol L−1 level for MOF, 1 × 10−3 pg mL−1 level for multiple metallic NPs composites and 1 × 10−2 pg mL−1 level for functionalized NPs | [ |
| Colorimetric PADs | Functionalized AuNPs and AgNPs, enzyme-like nanomaterials | Simplicity and convenience, readout with naked eye, rapidness, low cost and low sample consumption | Poor sensitivity, limited to qualitative or semi-quantitative analysis | 10 pg mL−1 level for functionalized AuNPs, 100 pmol L−1 level for functionalized AgNPs, 1 pmol L−1 level for enzyme-like nanomaterials | [ |
| Fluorometric PADs | NC, QD, CD, MOF | Low cost, easy operation | Reader-dependent | 1 pmol L−1 level for NC, 1 pg mL−1 level for QD, 1 × 103 pg mL−1 level for CD, 10 pg mL−1 level for MOF | [ |
| SERS PADs | AuNPs and AgNPs | On-site label-free detection, offered fingerprint signatures, high sensitivity | Equipment-dependent | 1 pg mL−1 level for AuNPs and AgNPs | [ |